> Legacy Education Alliance announced this week that it has settled credit card litigation and will receive an aggregate sum of $5.0 million in the settlement.
> The settlement will impact the company s 4Q17 financial statements. We estimate that the funds will equate to a one-time EPS benefit of $0.18 to $0.22 per share.
> The settlement funds will bolster the company s cash reserves that it can tap to further its growth initiatives.
> Consistent with the company s goal to be the leading global provider of services and products that enable people to assume control of their finances, Legacy has implemented several growth initiatives. These include international expansion and increased focus on enhancing the online delivery of its courses in order to provide greater flexibility in a digital world.
> Thus far, the company s measures have resulted in strong growth. For example, in the first half of 2017, Legacy s total cash sales advanced 16.4% year-over-year to $51.2 million.
> The company expects to achieve continued growth and margin expansion through product mix shifts, as it expands its online course delivery and evaluates opportunities to expand its course offerings, and brand development and price level improvements.
Recent LEAI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:25:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 07:36:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/31/2023 09:20:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:31:46 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:05:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 12:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 08:30:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/07/2023 05:22:04 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM